|1.||Tripathi, Trivendra: 1 article (08/2013)|
|2.||Abdi, Mahshid: 1 article (08/2013)|
|3.||Alizadeh, Hassan: 1 article (08/2013)|
|4.||Li, Rung-Chi: 1 article (08/2012)|
|5.||Sapirstein, Adam: 1 article (08/2012)|
|6.||Zhang, Jian: 1 article (08/2012)|
|7.||Barasch, Noah: 1 article (08/2012)|
|8.||Kim, Hae-Kyoung: 1 article (08/2012)|
|9.||Cho, Baik-Hwan: 1 article (08/2012)|
|10.||Jung, Sung-Won: 1 article (08/2012)|
|1.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
09/01/2007 - "Consistent with these findings, AACOCF3 reduced the development of both thermal hyperalgesia and mechanical allodynia, whereas diclofenac exacerbated thermal hyperalgesia, in CCI rats. "
04/01/2005 - "Secondly, we showed that intrathecal (i.t.) administration of MAFP and AACOCF3, but not BEL, dose-dependently prevented thermal hyperalgesia induced by intraplantar carrageenan as well as formalin-induced flinching. "
11/01/2004 - "The present study was carried out, using inhibitors to secretory phospholipase A2 (sPLA2, 12-epi-scalaradial), cytosolic phospholipase A2 (cPLA2, AACOCF3), or calcium-independent phospholipase A2 (iPLA2, bromoenol lactone), to compare possible contributions of central nervous PLA2 isoforms to the development of allodynia after facial carrageenan injection in mice. "
05/01/2012 - "Pyrrolidine-2 is a more potent and specific cPLA(2)α inhibitor than MAFP and AACOCF3 and represents an excellent pharmacological tool to investigate the biosynthesis and the biological roles of cancer. "
03/01/2009 - "In both tumor mouse models, treatment with AACOCF3 prior to irradiation significantly suppressed tumor growth and decreased overall tumor blood flow and vascularity. "
03/01/2009 - "In cell culture experiments, inhibition of cPLA2 with AACOCF3 prevented radiation-induced activation of ERK1/2 and decreased clonogenic survival of irradiated vascular endothelial cells but not the lung tumor cells. "
03/01/2009 - "For in vivo experiments, mice with LLC or H460 tumors in the hind limbs were treated for 5 consecutive days with 10 mg/kg AACOCF3 administered daily 30 minutes prior to irradiation. "
03/01/2009 - "Vascular endothelial cells (3B11 and MPMEC) and lung tumor cells (LLC and H460) were treated with 1 micromol/L AACOCF3 for 30 minutes prior to irradiation. "
06/27/2006 - "AACOCF3 treatment maintained the PO2 at a level similar to the vehicle group throughout reperfusion and reduced significantly the alveolar-capillary leakage, edema formation, and neutrophil extravasation. "
06/13/2006 - "Specifically, AACOCF3 inhibited phorbol 12-myristate 13-acetate (PMA)-induced chronic ear edema in mice. "
|1.||Peroxynitrous Acid (Peroxynitrite)
|2.||Phospholipases A2 (Phospholipase A2)
|3.||6- (bromomethylene)tetrahydro- 3- (1- naphthaleneyl)- 2H- pyran- 2- one
|4.||Calcium-Independent Phospholipases A2
|5.||Secretory Phospholipases A2
|7.||Protein Isoforms (Isoforms)
|9.||Matrix Metalloproteinase 14 (MT1-MMP)
|10.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)